Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors

Patritumab deruxtecan is an antibody–drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide‐based cleavable linker. As part of the pharmacometric analysis informing dose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2023-01, Vol.63 (1), p.77-90
Hauptverfasser:	Lu, Yasong, Shimizu, Shinji, Sawamura, Ryoko, Tajima, Naoyuki, He, Ling, Lee, Mark, Abutarif, Malaz, Shi, Rong
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Monoclonal, Humanized - pharmacokinetics antibody–drug conjugate Breast cancer Camptothecin Colorectal cancer Colorectal carcinoma DNA topoisomerase Epidermal growth factor HER3‐DXd Humans Immunoconjugates - pharmacokinetics Lung cancer modeling and simulation Monoclonal antibodies Neoplasms - drug therapy patritumab deruxtecan Pharmacokinetics Pharmacometrics population pharmacokinetics Receptor, ErbB-2 - metabolism Solid tumors Subpopulations Trastuzumab - pharmacokinetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!